Provided by Tiger Trade Technology Pte. Ltd.

Biomea Fusion, Inc.

1.37
+0.01000.74%
Post-market: 1.370.0041+0.30%19:30 EDT
Volume:575.26K
Turnover:774.04K
Market Cap:99.05M
PE:-2.91
High:1.38
Open:1.37
Low:1.32
Close:1.36
52wk High:2.99
52wk Low:0.8719
Shares:72.30M
Float Shares:67.01M
Volume Ratio:0.86
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4711
EPS(LYR):-1.1832
ROE:-164.14%
ROA:-63.46%
PB:8.16
PE(LYR):-1.16

Loading ...

Biomea Fusion Q1 Basic EPS USD -0.17

THOMSON REUTERS
·
May 12

Press Release: Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

Dow Jones
·
May 12

U.S. Earnings Preview: After Market Close May 8

Dow Jones
·
May 09

Biomea Fusion options imply 18.9% move in share price post-earnings

TIPRANKS
·
May 09

Biomea Fusion options imply 23.1% move in share price post-earnings

TIPRANKS
·
May 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 06

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

GlobeNewswire
·
May 06

Biomea Fusion Initiated at Market Outperform by Citizens

Dow Jones
·
May 05

Biomea Fusion initiated with an Outperform at Citizens

TIPRANKS
·
May 05

Biomea Fusion options imply 22.0% move in share price post-earnings

TIPRANKS
·
May 05

Biomea Fusion Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
May 02

U.S. Earnings Preview: After Market Close May 1

Dow Jones
·
May 02

Biomea Fusion Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Apr 28

Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY), Omnicell (OMCL) and Biomea Fusion (BMEA)

TIPRANKS
·
Apr 28

Oppenheimer Sticks to Its Buy Rating for Biomea Fusion (BMEA)

TIPRANKS
·
Apr 28

Biomea Fusion announces positive 52-week results from phase 2 COVALENT-112 trial

TIPRANKS
·
Apr 28

Biomea Fusion says icovamenib boosts C-peptide in 52-week Phase 2 type 1 diabetes trial

Reuters
·
Apr 28

Biomea Fusion Inc: Icovamenib Was Generally Well Tolerated, With No New or Unexpected Safety Signals Identified Throughout 52-Week Observation Period

THOMSON REUTERS
·
Apr 28

Biomea Fusion Announces Positive 52-Week Results From Phase 2 Covalent-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

THOMSON REUTERS
·
Apr 28

Biomea Fusion Inc: Based on Data Co Is Planning Phase 2 Trial in Collaboration With 4 U.S. Academic Centers

THOMSON REUTERS
·
Apr 28